PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26312482-1	2015	OBJECTIVE: Angiotensinogen exists in two distinct redox forms in plasma, the oxidized sulfhydryl-bridge form and the reduced, unbridged, free thiol form.	Sulfhydryl Compounds	142-147	angiotensinogen	Homo sapiens	11-26	
31069778-2	2019	Angiotensinogen is found in two distinct posttranslational forms in the plasma, an oxidized and a reduced (free thiol) form.	Sulfhydryl Compounds	112-117	angiotensinogen	Homo sapiens	0-15	
31069778-4	2019	We have developed novel ELISA assays to quantitate the levels of total and free thiol angiotensinogen allowing for calculation of the amount of oxidized angiotensinogen species.	Sulfhydryl Compounds	80-85	angiotensinogen	Homo sapiens	86-101	
26312482-2	2015	The oxidized form of angiotensinogen compared to the free thiol form preferentially interacts with renin resulting in increased generation of angiotensin.	Sulfhydryl Compounds	58-63	angiotensinogen	Homo sapiens	21-36	
26312482-7	2015	The oxidized angiotensinogen plasma level is derived by subtracting the level of free thiol, reduced angiotensinogen from the total angiotensinogen levels in the plasma.	Sulfhydryl Compounds	86-91	angiotensinogen	Homo sapiens	13-28	
26312482-10	2015	CONCLUSION: Patients with pre-eclampsia had substantially lower levels of free thiol angiotensinogen compared to healthy pregnant controls, whilst maintaining similar total angiotensinogen levels in the plasma.	Sulfhydryl Compounds	79-84	angiotensinogen	Homo sapiens	85-100	
20927107-5	2010	Here we show that the reduced unbridged form of angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidized sulphydryl-bridged form, which preferentially interacts with receptor-bound renin.	Sulfhydryl Compounds	134-144	angiotensinogen	Homo sapiens	48-63	
20927107-7	2010	Specifically, we demonstrate the oxidative switch of angiotensinogen to its more active sulphydryl-bridged form in the maternal circulation in pre-eclampsia-the hypertensive crisis of pregnancy that threatens the health and survival of both mother and child.	Sulfhydryl Compounds	88-98	angiotensinogen	Homo sapiens	53-68	
17941088-8	2008	The thiol antioxidant, N-acetyl cysteine (NAC), completely inhibited stretch- and Ang II-induced apoptosis.	Sulfhydryl Compounds	4-9	angiotensinogen	Homo sapiens	82-88	
1531616-7	1992	Production of 3"-phosphoglycolate residues, restricted mainly to the T of AGT in bistranded lesions, correlated with the incidence of direct DS breaks in the AGT.ACT model and in plasmid DNA and appeared to be influenced by the reducing power of the thiol activator.	Sulfhydryl Compounds	250-255	angiotensinogen	Homo sapiens	158-161	
12036910-6	2002	Although the S-nitrosylcysteine adduct in hAGT is readily reversible by reaction with other cellular thiols, the formation of S-nitrosocysteine at Cys-145 was found to lead to the rapid degradation of the hAGT protein in vivo.	Sulfhydryl Compounds	101-107	angiotensinogen	Homo sapiens	42-46	
1531616-0	1992	Neocarzinostatin-mediated DNA damage in a model AGT.ACT site: mechanistic studies of thiol-sensitive partitioning of C4" DNA damage products.	Sulfhydryl Compounds	85-90	angiotensinogen	Homo sapiens	48-51	
1531616-3	1992	Structure-function studies revealed that a variety of different thiols produced bistranded lesions in this model by predominantly C4"-hydrogen atom abstraction (84-93%) at the T of AGT and C5"-hydrogen atom abstraction (87-91%) at the T of ACT.	Sulfhydryl Compounds	64-70	angiotensinogen	Homo sapiens	181-184	
9030406-4	1997	A Glu-thiol inhibitor of aminopeptidase A also reduced angiotensin II-induced drinking.	Sulfhydryl Compounds	6-11	angiotensinogen	Homo sapiens	55-69	
2548550-9	1989	The intention was to replace the thiol side chain with a homophenylalanine unit to bind to the zinc ion and also to occupy the S1 site which fits the Phe8 side chain of angiotensin I.	Sulfhydryl Compounds	33-38	angiotensinogen	Homo sapiens	169-182